Literature DB >> 17310929

Resurfacing THA for patients younger than 50 year: results of 2- to 9-year followup.

Harlan C Amstutz1, Scott T Ball, Michel J Le Duff, Frederick J Dorey.   

Abstract

Resurfacing THA is an attractive treatment option for young patients because it saves the femoral head and is easily revisable. We assessed the clinical outcome of metal-on-metal hybrid total hip resurfacing for the treatment of 295 patients (350 hips) younger than 50 years of age (average, 41.2 years) and compared these results with those of patients 50 years or older (average, 57.4 years) at the time of surgery who were implanted with the same design. Seventy-five percent of the patients were male. The minimum followup was 2 years (mean 5.5 years; range 2-9 years). UCLA hip scores improved to 9.4 for pain; 9.6 for walking; 9.5 for function; and 7.6 for activity. We found no differences in survivorship between younger and older patients, and postoperative clinical scores related to the patients' physical health were comparable. There was no acetabular component loosening. Ten hips (2.8%) were revised for femoral aseptic loosening and one for femoral neck fracture. The 5-year survivorship of hips with good bone quality was 97.8%. There has been no femoral component loosening when the femoral stems were cemented irrespective of bone quality. Metal-on-metal resurfacing THA performs well at short to mid-term followup in young, active adults despite high activity levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17310929     DOI: 10.1097/BLO.0b013e318041f0e7

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  37 in total

1.  Imageless navigation of hip resurfacing arthroplasty increases the implant accuracy.

Authors:  C Schnurr; J W P Michael; P Eysel; D P König
Journal:  Int Orthop       Date:  2007-12-22       Impact factor: 3.075

2.  A simple technique for alignment in total hip resurfacing arthroplasty: technical note and preliminary report.

Authors:  Manuel Villanueva-Martínez; Antonio Ríos-Luna; Angel Villamor-Pérez
Journal:  HSS J       Date:  2009-06-09

3.  Ten different hip resurfacing systems: biomechanical analysis of design and material properties.

Authors:  Christian Heisel; Jennifer A Kleinhans; Michael Menge; Jan Philippe Kretzer
Journal:  Int Orthop       Date:  2008-07-04       Impact factor: 3.075

Review 4.  Surgical management of hip osteoarthritis.

Authors:  Rajiv Gandhi; Anthony V Perruccio; Nizar N Mahomed
Journal:  CMAJ       Date:  2013-10-21       Impact factor: 8.262

5.  Surface replacement is comparable to primary total hip arthroplasty.

Authors:  Mike S McGrath; David R Marker; Thorsten M Seyler; Slif D Ulrich; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2008-09-16       Impact factor: 4.176

6.  Hip resurfacing arthroplasty: risk factors for failure over 25 years.

Authors:  Eric J Yue; Miguel E Cabanela; Gavan P Duffy; Michael G Heckman; Mary I O'Connor
Journal:  Clin Orthop Relat Res       Date:  2008-09-24       Impact factor: 4.176

7.  [Reasons for failure of hip resurfacing implants. A failure analysis based on 250 revision specimens].

Authors:  M M Morlock; N Bishop; F Stahmer; J Zustin; G Sauter; M Hahn; M Krause; W Rüther; M Amling
Journal:  Orthopade       Date:  2008-07       Impact factor: 1.087

8.  Does hip resurfacing require larger acetabular cups than conventional THA?

Authors:  Florian D Naal; Michael S H Kain; Otmar Hersche; Urs Munzinger; Michael Leunig
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

Review 9.  [Metal-on-metal hybrid hip resurfacing. Development and current state].

Authors:  M Hoberg; M J Le Duff; H C Amstutz
Journal:  Orthopade       Date:  2008-07       Impact factor: 1.087

10.  Can patients return to high-impact physical activities after hip resurfacing? A prospective study.

Authors:  Julien Girard; Bruno Miletic; Anthony Deny; Henri Migaud; Nicolas Fouilleron
Journal:  Int Orthop       Date:  2013-03-02       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.